Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of atorvastatin and rosuvastatin on prevention of atrial fibrillation after coronary artery bypass graft
IRCT20191109045384N1Phase 2Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Feb 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of atorvastatin and rosuvastatin in Atrial fibrillation (AFib) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Incidence of postoperative atrial fibrillation. Started Feb 2019; status: completed.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20191109045384N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191109045384N1.